Literature DB >> 13784471

Hydroxy-phenylbutazone (Tanderil) in the treatment of ocular disease. A preliminary survey.

L E WERNER.   

Abstract

Entities:  

Keywords:  OPHTHALMOLOGY/therapy; PHENYLBUTAZONE/related compounds

Mesh:

Substances:

Year:  1960        PMID: 13784471      PMCID: PMC510033          DOI: 10.1136/bjo.44.12.755

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  4 in total

1.  The status of G-27202 (metabolite 1 of phenylbutazone) in the treatment of rheumatic disorders.

Authors:  W GRAHAM
Journal:  Can Med Assoc J       Date:  1960-05-14       Impact factor: 8.262

2.  The aetiology and treatment of uveitis.

Authors:  E S PERKINS
Journal:  Trans Ophthalmol Soc U K       Date:  1958

3.  Phenylbutazone and its derivatives with special reference to G.27202.

Authors:  F D HART; D BURLEY
Journal:  Br Med J       Date:  1959-04-25

4.  [Phenylbutazone & its use in ophthalmology].

Authors:  P SVANE-KNUDSEN
Journal:  Nord Med       Date:  1959-02-05
  4 in total
  3 in total

1.  Double-blind trial of the treatment of episcleritis-scleritis with oxyphenbutazone or prednisolone.

Authors:  P G Watson; D J Lobascher; D W Sabiston; E Lewis-Faning; P D Fowler; B R Jones
Journal:  Br J Ophthalmol       Date:  1966-08       Impact factor: 4.638

2.  Anti-inflammatory effect of oxyphenbutazone after cataract and squint operations.

Authors:  V H Smith; P D Fowler
Journal:  Br J Ophthalmol       Date:  1966-12       Impact factor: 4.638

3.  Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease.

Authors:  S M Podos
Journal:  Trans Am Ophthalmol Soc       Date:  1976
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.